Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Non-Current Deffered Revenue (2016 - 2017)

Arcadia Biosciences filings provide 4 years of Non-Current Deffered Revenue readings, the most recent being $2.0 million for Q4 2017.

  • On a quarterly basis, Non-Current Deffered Revenue fell 34.68% to $2.0 million in Q4 2017 year-over-year; TTM through Dec 2017 was $2.0 million, a 34.68% decrease, with the full-year FY2017 number at $2.0 million, down 34.68% from a year prior.
  • Non-Current Deffered Revenue hit $2.0 million in Q4 2017 for Arcadia Biosciences, down from $2.8 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $3.6 million in Q4 2014 to a low of $2.0 million in Q4 2017.
  • Median Non-Current Deffered Revenue over the past 4 years was $2.8 million (2017), compared with a mean of $2.8 million.
  • The widest YoY moves for Non-Current Deffered Revenue: up 28.44% in 2017, down 34.68% in 2017.
  • Arcadia Biosciences' Non-Current Deffered Revenue stood at $3.6 million in 2014, then dropped by 27.48% to $2.6 million in 2015, then grew by 18.32% to $3.1 million in 2016, then crashed by 34.68% to $2.0 million in 2017.
  • The last three reported values for Non-Current Deffered Revenue were $2.0 million (Q4 2017), $2.8 million (Q3 2017), and $2.9 million (Q2 2017) per Business Quant data.